At the time of writing, CytomX Therapeutics Inc [CTMX] stock is trading at $5.54, down -3.15%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CTMX shares have gain 30.35% over the last week, with a monthly amount glided 34.47%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
CytomX Therapeutics Inc [NASDAQ: CTMX] stock has seen the most recent analyst activity on January 20, 2026, when Guggenheim initiated its Buy rating and assigned the stock a price target of $10. Previously, Cantor Fitzgerald started tracking the stock with Overweight rating on September 22, 2025, and set its price target to $6. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $7 on July 31, 2025. H.C. Wainwright upgraded its rating to a Buy but $5 remained the price target by the analyst firm on May 15, 2025. In a note dated May 28, 2024, Piper Sandler upgraded an Overweight rating on this stock and boosted its target price from $2.25 to $3.50.
For the past year, the stock price of CytomX Therapeutics Inc fluctuated between $0.40 and $6.15. Currently, Wall Street analysts expect the stock to reach $8.75 within the next 12 months. CytomX Therapeutics Inc [NASDAQ: CTMX] shares were valued at $5.54 at the most recent close of the market. An investor can expect a potential return of 57.94% based on the average CTMX price forecast.
Analyzing the CTMX fundamentals
According to CytomX Therapeutics Inc [NASDAQ:CTMX], the company’s sales were 113.63M for trailing twelve months, which represents an -82.16% plunge. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at 0.2%, Pretax Profit Margin comes in at 0.25%, and Net Profit Margin reading is 0.25%. To continue investigating profitability, this company’s Return on Assets is posted at 0.18, Equity is 0.44 and Total Capital is 0.2. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that CytomX Therapeutics Inc [NASDAQ:CTMX] has a current ratio of 3.64. As well, the Quick Ratio is 3.64, while the Cash Ratio is 0.83. Considering the valuation of this stock, the price to sales ratio is 8.26, the price to book ratio is 8.52 and price to earnings (TTM) ratio is 13.25.
Transactions by insiders
Recent insider trading involved McCarthy Sean A., CEO, that happened on Nov 06 ’25 when 0.1 million shares were sold. CEO, Sean McCarthy completed a deal on Nov 06 ’25 to buy 0.1 million shares. Meanwhile, Chief Financial Officer Ogden Christopher sold 10614.0 shares on Jun 16 ’25.
